# US 2020/0390819 A1 · Erectile dysfunction therapeutic agent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390819 A1
- Document ID: US20200390819A1
- Status: Published application
- Kind: A1
- Application number: 16/971,738
- Filed: 2019-02-20
- Published: 2020-12-17
- Earliest claimed: 2018-02-23
- Assignees: Meis Technology Inc.
- Applicants: Meis Technology Inc.
- Inventors: Seiji Matsumoto; Tokunori Yamamoto; Yuji Hotta; Kazunori Kimura
- Web page: https://patentgrep.com/patent/US20200390819A1

## CPC

- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- A61K 31/5575: having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 15/10: for impotence
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An object of the present invention is to provide a novel therapeutic strategy for erectile dysfunction. Disclosed is a therapeutic agent for erectile dysfunction, including a filtrate obtained by filtering a disrupted solution of adipose tissue-derived stem cells or bone marrow-derived stem cells.

## Claims

### Claim 1

A therapeutic agent for erectile dysfunction, comprising a filtrate obtained by filtering a disrupted solution of adipose tissue-derived stem cells or bone marrow-derived stem cells.

### Claim 2 (depends on 1)

The therapeutic agent for erectile dysfunction according to claim 1, wherein the disrupted solution is centrifuged before the filtering, and an obtained supernatant is filtered.

### Claim 3 (depends on 1)

The therapeutic agent for erectile dysfunction according to claim 1, wherein the disrupted solution is obtained by ultrasonic treatment.

### Claim 4 (depends on 1)

The therapeutic agent for erectile dysfunction according to claim 1, which is used for treating organic erectile disorder or mixed erectile disorder.

### Claim 5 (depends on 4)

The therapeutic agent for erectile dysfunction according to claim 4, wherein the organic erectile disorder is neurogenic, vascular or diabetic erectile disorder.

### Claim 6 (depends on 1)

The therapeutic agent for erectile dysfunction according to claim 1, which is used in combination with a PDE-5 inhibitor and/or a prostaglandin preparation.

### Claim 7

A method for producing a therapeutic agent for erectile dysfunction, comprising following steps (1) to (3):
(1) disrupting adipose tissue-derived stem cells or bone marrow-derived stem cells;
(2) obtaining a filtrate by filtering a disrupted solution obtained in step (1), or a supernatant obtained by centrifuging the disrupted solution; and
(3) formulating the filtrate obtained in step (2).

### Claim 8 (depends on 7)

The production method according to claim 7, wherein step (1) is performed by ultrasonic treatment.

### Claim 9 (depends on 1)

A method for treating erectile dysfunction, comprising administering the therapeutic agent for erectile dysfunction according to claim 1, to the corpus cavernosum penis, the corpus spongiosum penis, the external urethral sphincter or under the urethral mucosa of the external urethral sphincter part of a patient with erectile dysfunction.

### Claim 10 (depends on 9)

The treatment method according to claim 9, wherein a PDE-5 inhibitor and/or a prostaglandin preparation is co-administered.
